Frontiers in Pharmacology · Nov 17, 2026
Phytoestrogens in the prevention and treatment of postmenopausal osteoporosis: molecular mechanisms, therapeutic evidence, and traditional Chinese medicine applications
By Li H, Xin L, Han X et al.
Postmenopausal osteoporosis (PMO) is driven by estrogen deficiency-related uncoupling of bone remodeling, with progressive bone loss and fracture susceptibility. We conducted a structured narrative review using searches of PubMed/MEDLINE, Web of Science Core Collection, Scopus, and China National Knowledge Infrastructure from inception to 27 August 2026. We evaluated cell and animal studies, observational studies, randomized trials, and meta-analyses separately. Established phytoestrogen classes, principally isoflavones, lignans, and coumestans, were distinguished from stilbenes included in broader classification schemes, coumarin-related plant metabolites, other isolated metabolites, botanical extracts, and multi-ingredient traditional Chinese medicine (TCM) preparations. Experimental studies support selected metabolite-specific effects on estrogen receptor, bone-remodeling, inflammatory, and redox pathways. Evidence for other proposed pathways and microbiota-mediated effects remains scarce or model-dependent. Human studies are heterogeneous and often involve generally healthy, early postmenopausal, or osteopenic women rather than patients with established PMO who are at high fracture risk. A 2024 meta-analysis of 63 randomized controlled trials (9,026 participants) found modest gains versus placebo at the lumbar spine (mean difference: 0.0175 g/cm ² ; 95% confidence interval: 0.0088–0.0263) and femoral neck (mean difference: 0.0172 g/cm ² ; 95% confidence interval: 0.0046–0.0298). These changes in bone mineral density (BMD) are surrogate outcomes and do not establish antifracture efficacy. Evidence for TCM-related isolated metabolites, botanical extracts, and multi-ingredient preparations is predominantly preclinical or limited by incomplete product characterization. Defined phytoestrogen preparations may warrant further study as adjuncts, but current evidence does not support replacing approved osteoporosis treatments.